Promising Alzheimer's vaccine draws closer to human trials, says researchers A DNA vaccine that was shown to reduce the accumulation…
Promising Alzheimer’s vaccine draws closer to human trials, says researchers
A DNA vaccine that was shown to reduce the accumulation of toxic proteins associated with Alzheimer’s disease in mice could move closer to human testing, according to researcher University of Texas Southwestern Medical Center.
>> Read more trendy news
A team with the center’s Peter Donnell Jr Brain Institute tested the vaccine, which the researchers said was an immune response that reduces the build up of toxic tau and beta amyloid proteins. Their results were published this week in medical journal Alzheimer’s research and therapy.
“This study is the culmination of a decade of research that has repeatedly shown that this vaccine can effectively and safely focus on animal models what we think can cause Alzheimer’s disease,” said Roger Rosenburg, chief executive of Alzheimer’s disease interview at UT Southwestern, in a press release. “I think we’re coming close to testing this therapy in humans.”
>> New treatment tested on mice could hold hope for Alzheimer’s patients, families
The vaccine is delivered to the skin and seems safe for humans, says researchers. It had previously been tested ̵
1; with similar results – in monkeys and rabbits.
The study published this week included tests on four cohorts consisting of between 15 and 24 mice each. It showed that the DNA vaccine developed by Rosenberg and his team “led to 40 percent reduction of beta amyloid and up to 50 percent reduction in rope, without any negative immune response,” according to UT Southwestern.
>> Read the study
No effective treatment is currently available for Alzheimer’s, the most common type of dementia. The disease often presents initially with mild memory loss and can develop to the point where it seriously affects a person’s ability to complete daily activities, according to Centers for Disease Control and Prevention.
>> Research shows reversal of Alzheimer’s disease in mice
As many as 5 million Americans lived with the disease 2014, the last year for which data were available, according to the CDC. Younger people sometimes get Alzheimer’s, but symptoms often occur after the age of 60, the agency reported.
“If disease emergence could be delayed by even five years, it would be huge for patients and their families,” Dr Doris Lambracht-Washington, the older author of the study, said in a press release. “The number of dementia diseases can fall by half.”
Several other therapies are also investigated and tested to treat the disease.